AlphaCentric Advisors’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

AlphaCentric Advisors’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-60,000	Closed	-$944K	–	260
2024 Q1	$944K	Buy	+60,000	New	+$923K	0.57%	66
2023 Q4	–	Sell	-132,000	Closed	-$1.68M	–	292
2023 Q3	$1.68M	Buy	132,000 +54,500	+70%	+$752K	0.95%	33
2023 Q2	$1.09M	Buy	77,500 +5,000	+7%	+$71.5K	0.61%	62
2023 Q1	$1.12M	Buy	+72,500	New	+$1.21M	0.77%	41
2020 Q3	–	Sell	-200	Closed	-$12K	–	178
2020 Q2	$12K	Buy	+200	New	+$10.7K	0.01%	133

Other funds holding DCPH

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

AlphaCentric Advisors's DCPH Position: Q2 2024 in Review

AlphaCentric Advisors sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 60,000 shares — an estimated $944K sold.

AlphaCentric Advisors first reported a position in DCPH in Q2 2020 and held it in 5 quarters. The position peaked at $1.68M in Q3 2023. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.

AlphaCentric Advisors reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
AlphaCentric Advisors sold 60,000 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $944K.
AlphaCentric Advisors first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 5 quarters.
AlphaCentric Advisors's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $1.68M in Q3 2023.
1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on AlphaCentric Advisors's 13F filing for Q2 2024, filed 25 Jul 2024.